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Dear Sir,
We read with much interest the recent study by Bahmanyar
et al. [1], where they tested the hypothesis that heterozygous
carriage of cystic fibrosis transmembrane conductance regulator
(CFTR) mutations may have a protective effect on the risk of
gastrointestinal (GI) diseases of the epithelial barrier, which
include inflammatory bowel diseases (IBD) such as Crohn's
disease (CD) and ulcerative colitis (UC). From the analysis of a
very large number of obligate carriers [parents and siblings of
cystic fibrosis (CF) patients] and non-carriers, and the
observation that GI diseases occur with similar frequencies in
these two groups, the authors conclude by ruling out the
existence of such protective effect.
We previously tested the same hypothesis by measuring the
occurrence of the most common CF mutation, F508del
(accounting for 70% of CFTR mutant copies), in 2568 subjects
from three independent cohorts of Italian, Swedish and Scottish
IBD patients and controls [2]. In our study, F508del
heterozygosity was significantly underrepresented both in
Italian and Swedish CD patients compared to controls (0.3%
vs 2.5% and 0% vs 1.6%, respectively), and it was absent in
Scottish CD patients with colonic involvement. In particular,
none of the 11 DeltaF508 heterozygous CD patients identified
(1 Italian and 10 Scottish) had a clinical picture characterized by
right-sided colitis.
CFTR can induce NF-kB activation upon binding to
lipopolysaccharide (LPS) from P. aeruginosa [3], and serves
as epithelial receptor for S. Typhi transluminal migration [4].
Regional differences in the composition of the gut flora have
been detected [5], and the inferred protective effect of F508del
heterozygosity in colonic CD may therefore come through
similar interactions with yet unidentified site-specific residing
bacteria.
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doi:10.1016/j.jcf.2010.10.006Although recruited through different study settings, Bahmanyar
et al. identified 7 CD patients out of 2930 CF obligate heteroygotes
in their survey.While larger numbers ofCF heterozygousCDcases
would be required to draw definitive conclusions, it would be
interesting to know both the nature of the CFTR mutation and the
site of intestinal damage in these 7 patients, before rejecting our
common hypothesis.References
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